Page last updated: 2024-11-03

ag 1879 and Triple Negative Breast Neoplasms

ag 1879 has been researched along with Triple Negative Breast Neoplasms in 2 studies

3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor

Triple Negative Breast Neoplasms: Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lou, L1
Yu, Z1
Wang, Y1
Wang, S1
Zhao, Y1
Tabariès, S1
Annis, MG1
Hsu, BE1
Tam, CE1
Savage, P1
Park, M1
Siegel, PM1

Other Studies

2 other studies available for ag 1879 and Triple Negative Breast Neoplasms

ArticleYear
c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
    Cancer science, 2018, Volume: 109, Issue:5

    Topics: Animals; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Epithelial-Mesenchymal Transition; Female; H

2018
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.
    Oncotarget, 2015, Apr-20, Volume: 6, Issue:11

    Topics: Animals; Apoptosis; Carcinoma; Cell Line, Tumor; Claudins; Dasatinib; Female; Gene Expression Regula

2015